Keywords
Plasma LPS
LBP level
Parkinson’s disease
Neurological function
Impact
Submitted : 2026-06-09
Accepted : 2026-06-24
Published : 2026-07-09
Abstract
Objective: To analyze the correlation between the levels of LPS (Lipopolysaccharide) and LBP (Lipopolysaccharide-binding protein) in feces and plasma and neurological function in patients with Parkinson’s disease (PD). Methods: Thirty patients with PD (PD group) who met the inclusion and exclusion criteria and were treated at the neurology outpatient clinic/inpatient department of Heilongjiang Provincial Hospital from March 2025 to December 2025 were selected. Thirty age- and gender-matched healthy individuals who underwent health screenings during the same period were selected as the healthy control group (HC group). The levels of LPS and LBP in feces and plasma were compared between the two groups. Results: After testing, the levels of LPS and LBP in feces and plasma of the PD group were significantly higher than those of the HC group. Among PD patients, the levels of LPS in feces of patients in stages III-V were significantly higher than those in stages I-II. The levels of LPS in the plasma of patients in stages III-V were significantly higher than those in stages I-II. The levels of LBP in feces and plasma of patients in stages III-V were significantly higher than those in stages I-II. There was a positive correlation between the levels of LPS in feces and the UPDRS (Unified Parkinson’s Disease Rating Scale) scores in PD patients (r=0.68, P<0.01). There was a positive correlation between the levels of LPS in plasma and the UPDRS scores (r=0.72, P<0.01). There was a positive correlation between the levels of LBP in feces and the UPDRS scores in PD patients (r=0.65, P<0.01). There was a positive correlation between the levels of LBP in plasma and the UPDRS scores (r=0.70, P<0.01). Conclusion: The levels of LPS and LBP in feces and plasma can serve as important indicators for evaluating patients with PD, and there is a positive correlation between these levels and neurological function in PD patients.
References
Ye SS, Wu SX, Huang J, et al., 2025, The Application Value of Skin Sympathetic Nerve Measurement, RR Interval Variability Combined with RAAS Detection in Orthostatic Hypotension of Parkinson’s Disease. Zhejiang Medical Journal, 47(14): 1484–1571.
Liu LJ, Kang T, Wang WC, et al., 2024, Study on the Relationship between Serum BDNF, IGF-1 and CysC Levels and Autonomic Dysfunction in Patients with Parkinson’s Disease. Progress in Modern Biomedicine, 24(22): 4268–4270.
Tang SP, 2025, Effects of α-lipoic Acid Combined with Dopamine Receptor Agonists on Cognitive Function and Neurotransmitters in Parkinson’s Disease. Medical Theory and Practice, 38(14): 2392–2395.
Liao S, Tang JW, Tang T, et al., 2025, Effects and Mechanisms of Dexmedetomidine on Neurological Function in Rats with Parkinson’s Disease. Chinese Journal of Geriatric Cardiology and Cerebrovascular Disease, 27(5): 650–655.
Lu LY, Wang L, 2024, Effects of Donepezil Combined with Madopar on Neuronal Apoptosis and Cognitive Function in Rats with Parkinson’s Disease. Chinese Journal of Immunology, 40(10): 2064–2070.
Chen MF, Liao J, Wang L, et al., 2025, Analysis of Latent Classes and Influencing Factors of Rapid Eye Movement Sleep Behavior Disorder in Patients with Parkinson’s Disease. Journal of Nurses Training, 40(12): 1291–1304.
Miao JD, Zhang YX, Tang H, et al., 2023, Effects of High-low Frequency Interactive rTMS on SCOPA-AUT Score, Cognitive Function and Motor Function in Patients with Mid-stage Parkinson’s Disease. Chinese Journal of Practical Nervous Diseases, 26(11): 1326–1330.
Liu Y, Xue L, Zhao J, et al., 2023, Clinical Characteristics in Early Parkinson’s Disease with Excessive Daytime Sleepiness: A Cross-sectional and Longitudinal Study. Clinical and Translational Science, 16(10): 2033–2045.
Xie SN, Jiang CG, Li XJH, et al., 2025, Incidence and Influencing Factors of Neuropsychiatric Dysfunction after Deep Brain Stimulation in Patients with Parkinson’s Disease: A Prospective Cohort Study. Union Medical Journal, 16(2): 300–306.
Tang T, Chen M, Yao SY, et al., 2024, Correlation between microRNA-497-5p and microRNA-331-5p and the Degree of Neurological Deficit in Patients with Ischemic Stroke. Chinese Journal of Geriatric Cardiology and Cerebrovascular Disease, 26(8): 911–915.
Chen JG, Peng JX, Yang YY, 2024, Efficacy of Pramipexole Combined with Dobasil in the Treatment of Parkinson’s Disease and its Effects on Activated T Cell Chemotactic Factor and α-synuclein. Youjiang Medical Journal, 52(7): 641–646.
Li S, Wen WJ, Ye W, et al., 2021, Phosphorylated α-synuclein Aggregated in Schwann Cells Exacerbates Peripheral Neuroinflammation and Nerve Dysfunction in Parkinson’s Disease through TLR2/NF-κB Pathway. Cell Death Discovery, 7(1): 289–289.